Objective To analyze the risk factors of progressive urinary incontinence in female patients with pelvic floor organ prolapse (pop) after pelvic floor reconstruction, and to construct its risk prediction model, so as to provide a clinical tool for predicting postoperative progressive SUI. Methods From May, 2019 to April, 2022, patients with pelvic floor organ prolapse with ICS-POP Q score ≥II, who underwent pelvic floor reconstruction in Yijishan Hospital of Wannan Medical College for 6 months, were retrospectively analyzed. The general clinical data and preoperative pelvic floor ultrasound results of 495 patients were collected and followed up. According to the occurrence of SUI before and after operation, it was divided into SUI improvement group and progressive group (including new and aggravated cases). Univariate and multivariate Logistic regression analysis was adopted, and the risk prediction model of progressive SUI after operation was established, and internal verification was carried out. R software rms package was used to construct its risk Nomogram. Results In this study, 76 patients developed progressive SUI after operation. Positive SUI in preoperative acupressure test, low position of Ba point indicated by POP-Q score, formation of small funnel in urethral orifice by pelvic floor ultrasound and levator ani avulsion are independent risk factors for postoperative progressive SUI. Combining the above four parameters, a model Logit P was established, with 0.515 as the cutoff value. The C- statistic of the model was 0.885(95%CI 0.737~0.936), and the Jordan index was 0.936. Sensitivity is 0.936, specificity is 0.737, positive likelihood ratio is 3.557, negative likelihood ratio is 0.087, diagnostic ratio is 40.885, positive predictive value is 0.911, negative predictive value is 0.800. Conclusion In this study, the Nomogram chart for predicting the risk of progressive SUI after pelvic floor reconstruction was finally established, which has a good prediction effect and provides clinical value for preoperative treatment of POP patients.